ABT vs ADM Stock Comparison

Scores Breakdown

Metric	ABT	ADM
📈 Growth	22/30	26/30
💰 Profitability	17/20	7/20
🏦 Financial Health	15/20	16/20
💵 Valuation	12/20	12/20
⚠️ Risk (lower is better)	4/10	6/10
Overall Score	72/100	65/100

Side-by-Side Summaries

ABT Analysis	ADM Analysis
📈 Growth & Financial Trajectory Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects). 💰 Margins & Cash Flow Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest. 🛡️ Balance Sheet & Liquidity Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience. ⚠️ Key Drivers & Risks Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios. Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.	📈 Growth & Financial Trajectory Over 8 quarters, ADM's Revenues moved in a narrow band around 19.9–20.5B, ending near 20.49B in Q1 2026 vs 19.94B at the start—a modest +2.9% gain. Net income progressed from about $18M in 2024 Q2 to $303M in 2026 Q1, with a peak of $567M in 2024 Q4, signaling improving profitability despite quarterly volatility. 💰 Margins & Cash Flow Gross margin remained steady at about 6.3%–6.8% across the period; operating margin hovered around 2%–3%. Operating cash flow was positive in most quarters (e.g., +4.30B in 2025 Q3, +1.81B in 2025 Q2, +0.15B in 2026 Q1), while investing cash flow was consistently negative, and financing activity varied, reflecting ongoing capital allocation. 🛡️ Balance Sheet & Liquidity Assets run around $52–53B with current assets about $26.6–29B and current liabilities near $18.0–19.6B, giving a healthy current ratio of roughly 1.3–1.5. Debt metrics show long-term debt around $7.6–8.3B and total liabilities around $29–33B, with equity in the low- to mid-$22B range, indicating solid balance-sheet resilience. ⚠️ Key Drivers & Risks Drivers: Commodity cycle for grains/oilseeds; global demand for ADM's processing and ingredients Risks: Commodity price volatility and cyclicality; macroeconomic sensitivity and valuation risk

ABT Analysis

ADM Analysis

📈 Growth & Financial Trajectory

Over the 8-quarter window, Revenue gravitated around $9.96B to $11.16B, ending at $11.16B in 2026 Q1, a start-to-end rise of about $1.2B (~12%). Net income remained positive through most quarters, with modest-to-strong fluctuations; several quarters show mid-single-digit billions in income, with notable variability from one-off items (e.g., tax effects).

💰 Margins & Cash Flow

Gross Margin was solid, around 56% on average (Gross Profit ~6.3B vs Revenues ~11.2B in 2026 Q1). Operating margin ranged roughly from 12% to 18%, peaking in 2025 Q2. Net cash flow from operating activities was consistently positive (e.g., 2026 Q1: $1.315B; prior quarters in the 1.4–2.9B range), while investing activities were typically cash outflows and financing modest.

🛡️ Balance Sheet & Liquidity

Total assets approximate $72B–$110B over the period with equity in the low-to-mid $50B range. The company shows a healthy current ratio (~~1.3–1.5) and modest long-term debt (~~$14–19B), supporting liquidity and balance sheet resilience.

⚠️ Key Drivers & Risks

Drivers: (1) Pharma/medical devices demand; (2) diversified product mix and recurring revenue from Rx/OTC portfolios.
Risks: (1) Regulatory/tax volatility and pricing pressure; (2) macro-cycle sensitivity and currency exposure.

📈 Growth & Financial Trajectory

Over 8 quarters, ADM's Revenues moved in a narrow band around 19.9–20.5B, ending near 20.49B in Q1 2026 vs 19.94B at the start—a modest +2.9% gain. Net income progressed from about $18M in 2024 Q2 to $303M in 2026 Q1, with a peak of $567M in 2024 Q4, signaling improving profitability despite quarterly volatility.

💰 Margins & Cash Flow

Gross margin remained steady at about 6.3%–6.8% across the period; operating margin hovered around 2%–3%. Operating cash flow was positive in most quarters (e.g., +4.30B in 2025 Q3, +1.81B in 2025 Q2, +0.15B in 2026 Q1), while investing cash flow was consistently negative, and financing activity varied, reflecting ongoing capital allocation.

🛡️ Balance Sheet & Liquidity

Assets run around $52–53B with current assets about $26.6–29B and current liabilities near $18.0–19.6B, giving a healthy current ratio of roughly 1.3–1.5. Debt metrics show long-term debt around $7.6–8.3B and total liabilities around $29–33B, with equity in the low- to mid-$22B range, indicating solid balance-sheet resilience.

⚠️ Key Drivers & Risks

Drivers: Commodity cycle for grains/oilseeds; global demand for ADM's processing and ingredients
Risks: Commodity price volatility and cyclicality; macroeconomic sensitivity and valuation risk

Similar Companies

ABBV Score: 59 BSX Score: 81 ELV Score: 77 ISRG Score: 85 JNJ Score: 79 MDT Score: 67 TMO Score: 75 TSLA Score: 62

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"